4-(嘧啶-2-基)苯甲酸 | 199678-12-1

• 物质功能分类: 医药中间体 - 杂环化合物 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(嘧啶-2-基)苯甲酸
• 中文别名: 4-嘧啶-2-苯甲酸
• 英文名称: 4-(pyrimidin-2-yl)benzoic acid
• 英文别名: 4-pyrimidin-2-ylbenzoic acid
• CAS: 199678-12-1
• 化学式: C₁₁H₈N₂O₂
• mdl: MFCD01318668
• 分子量: 200.197
• InChiKey: WNDAEOTYLPWXPN-UHFFFAOYSA-N

物化性质

• 熔点：
  238 °C
• 沸点：
  301.5±34.0 °C(Predicted)
• 密度：
  1.302±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  63.1
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2933599090
• 危险品标志：
  Harmful
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-(Pyrimidin-2-yl)benzoic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-(Pyrimidin-2-yl)benzoic acid
CAS number: 199678-12-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C11H8N2O2
Molecular weight: 200.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-(嘧啶-2-基)苯甲酸 在 tetrakis(acetonitrile)copper(I)tetrafluoroborate 、 TBAF(tBuOH)4 、 copper(II) bis(trifluoromethanesulfonate) 作用下， 以 乙腈 为溶剂， 反应 24.5h， 以56%的产率得到2-(4-fluorophenyl)pyrimidine
  参考文献：
  名称：

  苯甲酸的自由基脱羧碳金属化：芳族脱羧氟化的解决方案

  摘要：

  丰富的芳香羧酸存在于自然界和合成中的巨大结构多样性中。迄今为止，苯甲酸的具有合成价值的脱羧官能化主要是通过过渡金属催化的脱羧交叉偶联来实现的。然而，通常需要 140 °C 反应温度的热脱羧碳金属化的高活化能垒限制了底物范围以及可以维持这种条件的合适反应的范围。许多反应，例如，为脂肪族羧酸很好地开发的脱羧氟化，对于芳香族对应物来说，用当前的反应化学是无法实现的。这里，我们报告了一种概念上不同的方法，通过低势垒光诱导配体到金属电荷转移 (LMCT) 启用自由基脱羧碳金属化策略，该策略生成假定的高价芳基铜 (III) 配合物，从中可以发生通用的轻松还原消除。我们证明了我们的新方法适用于解决以前未实现的苯甲酸的一般脱羧氟化。

  DOI：

  10.1021/jacs.1c02490
• 作为产物：
  描述：

  4-(2-嘧啶)苯甲醛 在 sodium chlorite 、 sodium dihydrogenphosphate 、 2-甲基-2-丁烯 作用下， 以 水 、 叔丁醇 为溶剂， 反应 2.0h， 生成 4-(嘧啶-2-基)苯甲酸
  参考文献：
  名称：

  Biarylcarboxybenzamide derivatives as potent vanilloid receptor (VR1) antagonistic ligands

  摘要：

  Seventeen biarylcarboxybenzamide derivatives were prepared for the study of their agonistic/antagonistic activities to the vanilloid receptor (VR1) in rat DRG neurons. The replacement of the piperazine moiety of the lead compound I with phenyl ring showed quite enhanced antagonistic activity. Among the prepared derivatives, N-(4-tert-butylphenyl)-4-pyridine-2-yl-benzamide (2, IC50 = 31 nM) and N-(4-tet-t-butylphenyl)-4-(3-methylpyridine-2-yl)benzamide (3g, IC50 = 31 nM), showed 5-fold higher antagonistic activity than 1 in Ca-45 (2+)-influx assay. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.11.033

文献信息

• Pyrrolobenzodiazepine pyridine carboxamides and derivatives as follicle-stimulating hormone receptor antagonists
  申请人：Failli A. Amedeo

  公开号：US20060287522A1

  公开（公告）日：2006-12-21

  This invention provides pyrrolobenzodiazepine pyridine carboxamides selected from those of Formula (1), which act as follicle stimulating hormone receptor antagonists. The invention also provides pharmaceutical compositions and methods of treatment utilizing the compounds of Formulae (1) and (2).

  这项发明提供了从式（1）中选择的吡咯苯并二氮杂吡咯烷吡啶羧酰胺，其作为卵泡刺激素受体拮抗剂。该发明还提供了利用式（1）和（2）化合物的药物组合物和治疗方法。
• C–H and N–H Bond Annulation of Benzamides with Isonitriles Catalyzed by Cobalt(III)
  作者：Deepti Kalsi、Nagaraju Barsu、Pardeep Dahiya、Basker Sundararaju

  DOI：10.1055/s-0036-1589011

  日期：2017.9

  in a ‘green’ solvent. Vinylamides were also used similarly with tert-butyl isonitrile to give 3-(tert-butylimino)-1-quinolin-8-yl-1H-pyrrol-2(5H)-ones. A simple efficient, atom-economical procedure was developed for the cobalt-catalyzed C–H bond annulation of benzamides with isonitriles under mild conditions. The reaction tolerates a variety of functional group including heterocycles. Diverse 3-(al

  作为有机合成中的专题钴的一部分出版 纪念村桥俊介教授在钴催化的CH键功能化方面的开拓性工作 抽象的 开发了一种简单有效的，原子经济的方法，用于在温和条件下用异腈将钴酰胺与异腈进行钴催化的C–H键环化。该反应可耐受包括杂环在内的各种官能团。使用异腈作为C1源，通过C–H和N–H键环化，通过C–合成了各种3-（烷基亚氨基）-2-喹啉-8-基-2,3-二氢-1 H-异吲哚-1-酮在“绿色”溶剂中的H键活化。乙烯基酰胺也与叔丁基异腈类似地使用，得到3-（叔丁基亚氨基）-1-喹啉-8-基-1H-吡咯-2（5H）-。 开发了一种简单有效的，原子经济的方法，用于在温和条件下用异腈将钴酰胺与异腈进行钴催化的C–H键环化。该反应可耐受包括杂环在内的各种官能团。使用异腈作为C1源，通过C–H和N–H键环化，通过C–合成了各种3-（烷基亚氨基）-2-喹啉-8-基-2,3-二氢-1 H-异吲哚-1-酮在“绿色”溶
• LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism
  作者：Marie-Céline Frantz、Lucie P. Pellissier、Elsa Pflimlin、Stéphanie Loison、Jorge Gandía、Claire Marsol、Thierry Durroux、Bernard Mouillac、Jérôme A. J. Becker、Julie Le Merrer、Christel Valencia、Pascal Villa、Dominique Bonnet、Marcel Hibert

  DOI：10.1021/acs.jmedchem.8b00697

  日期：2018.10.11

  affinity and efficacy of representative ligands of the V1a and V2 vasopressin receptor subtypes (V1a-R and V2-R) and of the oxytocin receptor. Our results confirm the subtlety of the structure–affinity and structure–efficacy relationships around vasopressin/oxytocin receptor ligands and lead however to the first nonpeptide OT receptor agonist active in a mouse model of ASD after peripheral ip administration

  催产素（OT）及其受体（OT-R）与自闭症谱系障碍（ASD）的病因有关，并且OT-R是治疗干预的潜在目标。当前已经报道了极少的非肽催产素激动剂。它们的分子和体内药理学仍有待阐明，并且没有显示它们在改善与ASD相关的动物模型中的社会互动方面有效。为了合理设计中枢活性非肽全激动剂的设计，我们以系统的方式研究了V 1a和V 2加压素受体亚型（V 1a -R和V 2）的代表性配体的亲和力和功效的结构决定因素。-R）和催产素受体。我们的研究结果证实了血管加压素/催产素受体配体周围的结构亲和力和结构功效关系的微妙之处，但是导致了在外围腹膜内注射后在ASD小鼠模型中首个活性的非肽OT受体激动剂。
• [EN] COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING INFLAMMATORY DISEASES<br/>[FR] COMPOSÉS, COMPOSITION PHARMACEUTIQUE ET MÉTHODES À UTILISER DANS LE TRAITEMENT DE MALADIES INFLAMMATOIRES
  申请人：EUROSCREEN SA

  公开号：WO2015078949A1

  公开（公告）日：2015-06-04

  The present invention is directed to compounds of formula (I), useful in treating and/or preventing inflammatory diseases.

  本发明涉及一种化合物，其化学式为(I)，用于治疗和/或预防炎症性疾病。
• KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE
  申请人：Imago Biosciences, Inc.

  公开号：US20160237043A1

  公开（公告）日：2016-08-18

  Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.

  本文披露了新化合物和组合物，以及它们作为药物治疗疾病的应用。还提供了抑制KDM1A的方法，增加γ球蛋白基因表达的方法，以及诱导人类或动物主体中癌细胞分化的方法，用于治疗急性髓性白血病等疾病。